<DOC>
	<DOC>NCT02724228</DOC>
	<brief_summary>This is a Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia. The primary objective is to evaluate the long-term safety and tolerability of daily SC injections of BMN 111 in children with ACH who have completed two years of treatment in the 111-202 study.</brief_summary>
	<brief_title>A Study to Evaluate Long-Term Safety, Tolerability, &amp; Efficacy of BMN 111 in Children With Achondroplasia (ACH)</brief_title>
	<detailed_description />
	<mesh_term>Achondroplasia</mesh_term>
	<mesh_term>Natriuretic Peptide, C-Type</mesh_term>
	<criteria>Have completed 24 months of BMN 111 treatment in Study 111202. Parent(s) or guardian(s) are willing and able to provide written, signed informed consent. If sexually active, willing to use a highly effective method of contraception while participating in the study. Willing and able to perform all study procedures as physically possible Parents/caregivers willing to administer daily injections to the subjects and complete the required training. Requires any investigational agent prior to completion of study period. Have a condition or circumstance that, in the view of the Investigator, places the subject at high risk for poor treatment compliance or for not completing the study. Concurrent disease or condition that, in the view of the Investigator, would interfere with study participation or safety evaluations for any reason. Permanently discontinued BMN 111 during the 111202 study. Subject is pregnant. Current chronic therapy with restricted medications.</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Achondroplasia</keyword>
	<keyword>Dwarfism</keyword>
	<keyword>Bone Diseases, Developmental</keyword>
	<keyword>Bone Diseases</keyword>
</DOC>